Editorial: Current research, knowledge and controversies on high density lipoprotein

Current Medicinal Chemistry

Volumn 21, Issue 25, 2014, Pages 2853-2854

  Banach, Maciej ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN;

EDITORIAL; ELECTROPHORETIC MOBILITY; HUMAN; KNOWLEDGE; MEDICAL RESEARCH; METABOLIC REGULATION; METABOLISM; PUBLICATION;

HUMANS; LIPOPROTEINS, HDL; PERIODICALS AS TOPIC;

EID: 84906085422     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140716090648     Document Type: Editorial

References (27)

1. Serban, C.; Muntean, D.; Mikhailids, D.P.; Toth, P.P.; Banach, M. Dysfunctional HDL: The journey from savior to slayer. Clin. Lipidol., 2014, 9(1), 49-59.
2. Toth, P.P.; Barylski, M.; Nikolic, D.; Rizzo, M.; Montalto, G.; Banach, M. Should low high-density lipoprotein cholesterol (HDL-C) be treated? Best Pract. Res. Clin. Endocrinol. Metab., 2014, 28(3), 353-368.
3. Davidson, W.S.; Silva, R.A.; Chantepie, S.; Lagor, W.R.; Chapman, M.J.; Kontush, A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol., 2009, 29(6), 870-876.
4. Gluba, A.; Pietrucha, T.; Banach, M.; Piotrowski, G.; Rysz, J. The role of polymorphisms within paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the modulation of cardiovascular risk: a pilot study. Angiology, 2010, 61(2), 157-165.
5. Tomic, S.; Brkic, S.; Maric, D.; Mikic, A.N. Lipid and protein oxidation in female patients with chronic fatigue syndrome. Arch. Med. Sci., 2012, 8(5), 886-891.
6. Yilmaz, N. Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases. Arch. Med. Sci., 2012, 8(1), 138-153.
7. Banach, M.; Serban, C.; Aronow, W.S.; Rysz, J.; Dragan, S.; Lerma, E.V.; Apetrii, M.; Covic, A. Lipid, blood pressure and kidney update 2013. Int. Urol. Nephrol., 2014, 46(5), 947-961.
8. Rosenson, R.S.; Brewer, H.B. Jr.; Chapman, M.J.; Fazio, S.; Hussain, M.M.; Kontush, A.; Krauss, R.M.; Otvos, J.D.; Remaley, A.T.; Schaefer, E.J. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem., 2011, 57(3), 392-410.
9. Burchardt, P.; Zurawski, J.; Zuchowski, B.; Kubacki, T.; Murawa, D.; Wiktorowicz, K.; Wysocki, H. Low-density lipoprotein, its susceptibility to oxidation and the role of lipoprotein-associated phospholipase A2 and carboxyl ester lipase lipases in atherosclerotic plaque formation. Arch. Med. Sci., 2013, 9(1), 151-158.
10. Kontush, A.; Chapman, M.J. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr. Opin. Lipidol., 2010, 21(4), 312-318.
11. Barylski, M.; Mayszko, J.; Rysz, J.; Myliwiec, M.; Banach, M. Lipids, blood pressure, kidney -what was new in 2011? Arch. Med. Sci., 2011, 7(6), 1055-1066.
12. Rizzo, M.; Barylski, M.; Rizvi, A.A.; Montalto, G.; Mikhailidis, D.P.; Banach, M. Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia? Curr. Pharm. Des., 2013, 19(21), 3858-3868.
13. Otocka-Kmiecik, A.; Mikhailidis, D.P.; Nicholls, S.J.; Davidson, M.; Rysz, J.; Banach, M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog. Lipid Res., 2012, 51(4), 314-324.
14. Fendler, W.; Rizzo, M.; Borowiec, M.; Malachowska, B.; Antosik, K.; Szadkowska, A.; Banach, M.; Urbanska-Kosinska, M.; Szopa, M.; Malecki, M.; Mlynarski, W. Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level. Acta Diabetol., 2014, [Epub ahead of print].
15. Banach, M. Investigating DYS functional-HDL in selected groups of patients at high risk of cardiovascular events (DYS-HDL study) -Protocol and organization. J. Mol. Biomark. Diagn., 2014, 5(2), 120.
16. Ossoli, A.; Gomaraschi, M.; Franceschini, G.; Calabresi, L. Genetic Determinants of HDL Metabolism. Curr. Med. Chem., 2014, 21(25), 2855-2863.
17. Kardassis, D.; Mosialou, I.; Kanaki, M.; Tiniakou, I.; Thymiakou, E. Metabolism of HDL and its Regulation. Curr. Med. Chem., 2014, 21(25), 2864-2880.
18. Rizzo, M.; Otvos, J.D.; Nikolic, D.; Montalto, G.; Toth, P.P.; Banach, M. Subfractions and Subpopulations of HDL: An Update. Curr. Med. Chem., 2014, 21(25), 2881-2891.
19. Oravec, S.; Dukat, A.; Gavornik, P.; Kucera, M.; Gruber, K.; Gaspar, L.; Rizzo, M.; Toth, P.P.; Mikhailidis, D.P.; Banach, M. Atherogenic Versus Non-Atherogenic Lipoprotein Profiles in Healthy Individuals. Is there a Need to Change our Approach to Diagnosing Dyslipidemia? Curr. Med. Chem., 2014, 21(25), 2892-2901.
20. Kucera, M.; Oravec, S.; Hirnerova, E.; Huckova, N.; Celecova, Z.; Gaspar, L.; Banach, M. Effect of Atorvastatin on Low-Density Lipoprotein Subpopulations and Comparison between Indicators of Plasma Atherogenicity: A Pilot Study. Angiology, 2014, [Epub ahead of print].
21. Madahian, S.; Navab, K.D.; Pourtabatabaei, N.; Seyedali, S.; Safar, S.; Vazirian, S.; Hough, G. Inflammation, High Density Lipoprotein and Endothelium. Curr. Med. Chem., 2014, 21(25), 2902-2909.
22. Rysz, J.; Gluba, A.; Fliser, D.; Speer, T.; Wiecek, A. Chronic Kidney Disease -different role for HDL? Curr. Med. Chem., 2014, 21(25), 2910-2916.
23. Katsiki, N.; Athyros, V.G.; Karagiannis, A.; Mikhailidis, D.P. High-Density Lipoprotein, Vascular Risk, Cancer and Infection: a Case of Quantity and Quality? Curr. Med. Chem., 2014. 21(25), 2917-2926.
24. Dragan, S.; Serban, C.; Banach, M. Can We Change the Functionality of HDL Cholesterol with Non-Pharmacological and Pharmacological Agents? Curr. Med. Chem., 2014. 21(25), 2927-2946.
25. Katsiki, N.; Nikolic, D.; Montalto, G.; Banach, M.; Mikhailidis, D.P.; Rizzo, M. The role of fibrate treatment in dyslipidemia: an overview. Curr. Pharm. Des., 2013, 19(17), 3124-3131.
26. Duong, M.N.; Nicholls, S.J. New Drugs for HDL-C Disorders: the Beginning. Curr. Med. Chem., 2014, 21(25), 2947-2951.
27. Barylski, M.; Toth, P.P.; Nikolic, D.; Banach, M.; Rizzo, M.; Montalto, G. Emerging therapies for raising high-density lipoprotein cholesterol (HDLC) and augmenting HDL particle functionality. Best Pract. Res. Clin. Endocrinol. Metab., 2014, 28(3), 453-461.